**Executive Summary**
This report details the resilience of India's pharmaceutical export sector following the Sigachi Industries industrial accident in Telangana. Despite localized disruptions, pharmaceutical exports grew by 9.7% to USD 30.45 billion in 2025, supported by government efforts to enforce manufacturing standards and maintain international trade relations. The document emphasizes ongoing compliance with safety codes and the role of regulatory bodies in ensuring supply chain stability.
**Key Points / Main Content**
* **Export Performance and Resilience**
* India’s pharmaceutical exports rose from USD 27.75 billion in 2024 to USD 30.45 billion in 2025.
* The 9.7% growth rate indicates steady expansion despite the localized impact of the Sigachi Industries explosion.
* **Quality and Regulatory Oversight**
* The Central Drugs Standard Control Organisation (CDSCO) and State licensing authorities continue to enforce good manufacturing practices.
* Government bodies facilitate the exchange of information and compliance documents to address international safety or compliance concerns.
* **Trade Diplomacy and Market Access**
* Bilateral trade discussions are maintained through Joint Working Groups, Fast Track Mechanisms, and Joint Trade Committees.
* These forums aim to ensure supply chain resilience, prevent non-tariff barriers, and protect trade flows from being adversely affected by isolated industrial incidents.
* **Safety Compliance and Enforcement**
* All factories must legally adhere to the Occupational Safety, Health and Working Conditions Code, 2020.
* Compliance is reinforced through safety awareness programs, specialized training for safety officers, and continuous inspection drives.
**Impact Analysis**
**Pharmaceutical Exporters**
**Impact:** Beneficiaries of sustained market access and diplomatic support to counter potential trade barriers or safety concerns.
**Action Required:** Coordinate with export promotion agencies and Indian Missions to provide necessary compliance documentation when queried by international partners.
**Manufacturing Facilities and Factories**
**Impact:** Subject to mandatory legal compliance with updated safety codes and increased regulatory scrutiny.
**Action Required:** Ensure strict adherence to the Occupational Safety, Health and Working Conditions Code, 2020, and enroll safety officers in mandatory training and awareness programs.
**Government and Regulatory Authorities (CDSCO/State Bodies)**
**Impact:** Responsible for intensified enforcement of quality standards and safety protocols across the industry.
**Action Required:** Execute special inspection drives and safety awareness initiatives to ensure industry-wide adherence to prescribed protocols.
Key Entities Referenced
Occupational Safety, Health and Working Conditions Code, 2020: The primary legislation under which factories are legally required to comply with safety provisions and adherence to prescribed protocols.
Central Drugs Standard Control Organisation (CDSCO): The national regulatory body responsible for enforcing good manufacturing practices to ensure the quality and safety of Indian pharmaceutical products.
Department of Pharmaceuticals: The primary government department overseeing the pharmaceutical sector's performance, export resilience, and safety compliance.
Sigachi Industries, Telangana: The location of the industrial accident that serves as the context for the government’s report on pharmaceutical export stability.
Ministry of Chemicals and Fertilizers :
Department of Pharmaceuticals
Pharmaceutical Exports Post-Sigachi Industrial
Accident
Posted On: 27 MAR 2026 4:25PM by PIB Delhi
While the Sigachi Industries explosion in Telangana has caused a localised disruption, India’s overall
export of pharmaceutical products remain resilient. India’s exports of pharmaceuticals increased from
USD 27.75 billion in the Calendar Year 2024 to USD 30.45 billion in the Calendar Year 2025, reflecting a
growth of approximately 9.7%, indicating a steady expansion in India’s pharmaceutical export
performance.
The Government, through the Central Drugs Standard Control Organisation and State licensing
authorities, continues to enforce good manufacturing practices to ensure quality and safety of Indian
pharmaceutical products.
The Government engages in regular bilateral trade discussions through various forums including Joint
Working Groups, Fast Track Mechanisms, Joint Commission Meetings and Joint Trade Committees, to
ensure sustained market access, broad economic security and supply chain resilience. These dialogues
serve to address trade-related queries and prevent unilateral actions or non-tariff barriers, and ensure that
isolated industrial incidents do not adversely affect overall trade flows.
The Government including the export promotion agencies and Indian Missions abroad coordinate
whenever concerns regarding safety or compliance are raised and facilitate the necessary exchange of
information and compliance documents from exporters to address such queries/concerns effectively.
All factories are legally required to comply with safety provisions under the Occupational Safety, Health
and Working Conditions Code, 2020. In order to reinforce compliance, safety awareness programmes,
training of safety officers and special inspection, drives are undertaken to ensure adherence to prescribed
safety protocols on a continuous basis.
This information was given by Minister of State for Chemicals and Fertilizers, Smt. Anupriya Patel, in a
written reply in the Lok Sabha today.
*****
PC/PM
(Release ID: 2246065) Visitor Counter : 64
Read this release in: Urdu , ही